Selected data models

You must log in to select data models for download or further analysis.

16 Search results.
Relevance Rating New first Old first

Corticosteroid Medication Week 38 Mepolizumab HES NCT00086658 - Corticosteroid Medication Week 38

- 7/14/17 - 1 form, 1 itemgroup, 1 item, 1 language
Itemgroup: Corticosteroid Medication
Study part: Corticosteroid Medication Week 38/ Early Withdrawal visit. A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Corticosteroid Medication Week 32 Mepolizumab HES NCT00086658 - Corticosteroid Medication Week 32

- 7/12/17 - 1 form, 1 itemgroup, 1 item, 1 language
Itemgroup: Corticosteroid Medication
Study part: Corticosteroid Medication Week 32. A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Corticosteroid Medication Week 28 Mepolizumab HES NCT00086658 - Corticosteroid Medication Week 28

- 7/12/17 - 1 form, 1 itemgroup, 1 item, 1 language
Itemgroup: Corticosteroid Medication
Study part: Corticosteroid Medication Week 28. A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Corticosteroid Medication Week 24 Mepolizumab HES NCT00086658 - Corticosteroid Medication Week 24

- 7/12/17 - 1 form, 1 itemgroup, 1 item, 1 language
Itemgroup: Corticosteroid Medication
Study part: Corticosteroid Medication Week 24. A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Corticosteroid Medication Week 20 Mepolizumab HES NCT00086658 - Corticosteroid Medication Week 20

- 7/12/17 - 1 form, 1 itemgroup, 1 item, 1 language
Itemgroup: Corticosteroid Medication
Study part: Corticosteroid Medication Week 20. A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Corticosteroid Medication Week 16 Mepolizumab HES NCT00086658 - Corticosteroid Medication Week 16

- 7/12/17 - 1 form, 1 itemgroup, 1 item, 1 language
Itemgroup: Corticosteroid Medication
Study part: Corticosteroid Medication Week 16. A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Corticosteroid Medication Week 12 Mepolizumab HES NCT00086658 - Corticosteroid Medication Week 12

- 7/10/17 - 1 form, 1 itemgroup, 1 item, 1 language
Itemgroup: Corticosteroid Medication
Study part: Corticosteroid Medication Week 12. A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Corticosteroid Medication Weeks 9- 11 Mepolizumab HES NCT00086658 - Corticosteroid Medication Weeks 9- 11

- 7/10/17 - 1 form, 1 itemgroup, 1 item, 1 language
Itemgroup: Corticosteroid Medication
Study part: Corticosteroid Medication Weeks 9- 11. A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Corticosteroid Medication Week 8 Mepolizumab HES NCT00086658 - Corticosteroid Medication Week 8

- 7/9/17 - 1 form, 1 itemgroup, 1 item, 1 language
Itemgroup: Corticosteroid Medication
Study part: Corticosteroid Medication Week 8. A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Corticosteroid Medication Weeks 5 - 7 Mepolizumab HES NCT00086658 - Corticosteroid Medication Weeks 5 - 7

- 7/9/17 - 1 form, 1 itemgroup, 1 item, 1 language
Itemgroup: Corticosteroid Medication
Study part: Corticosteroid Medication Weeks 5 - 7. A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Corticosteroid Medication Week 4 Mepolizumab HES NCT00086658 - Corticosteroid Medication Week 4

- 6/11/17 - 1 form, 1 itemgroup, 1 item, 1 language
Itemgroup: Corticosteroid Medication
Study part: Corticosteroid Medication Week 4. A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Corticosteroid Medication Week 1-3 Mepolizumab HES NCT00086658 - Corticosteroid Medication Week 1-3

- 6/11/17 - 1 form, 1 itemgroup, 1 item, 1 language
Itemgroup: Corticosteroid Medication
Study part: Corticosteroid Medication Week 1-3. A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial